Put companies on watchlist
bonyf NV
ISIN: BE6333353298
WKN:
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

bonyf NV · ISIN: BE6333353298 · EQS - Company News (2 News)
Country: Belgium · Primary market: Belgium · EQS NID: 2040479
28 November 2024 11:20AM

bonyf expands its global formulation footprint through a strategic alliance with Group Pharmaceuticals Ltd, signing a license agreement to produce NitrAdine® for India


bonyf NV / Key word(s): Alliance/Agreement
bonyf expands its global formulation footprint through a strategic alliance with Group Pharmaceuticals Ltd, signing a license agreement to produce NitrAdine® for India

28-Nov-2024 / 11:20 CET/CEST


bonyf expands its global NitrAdine® formulation footprint through its latest strategic alliance achievement with Group Pharmaceuticals Ltd, by a license agreement to produce NitrAdine® denture cleansing and disinfecting tablets for India

fncls.ssp?fn=download2_file&code_str=b3b2ab14065c4f69359aec60c13cbab4

Knokke-Heist (Belgium), 28 November 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production, and marketing of oral, denture, orthodontic, and wound care products. bonyf NV and Group pharmaceuticals Ltd are pleased to announce a strategic alliance with a license agreement on the NitrAdine® formulation to manufacture and distribute in India the bonyf products NitrAdine® denture cleansing & disinfecting tablets.

bonyf NV is a Belgian company with its R&D department in Liechtenstein and its manufacturing facility in Switzerland founded in 1979 moves forward with its fast global expanding coverage. The innovative driven bonyf R&D department, bonyf AG based in Liechtenstein, develops unique, patented healthy denture fixative creams and the most efficient disinfecting denture tablets based on extensive clinical evidence. The manufacturing facility bonyf Production AG ensures the production of denture products according to the highest worldwide standards. bonyf Regulatory department excels in global regulatory expertise and successful registration support services. The bonyf group offers customers worldwide, products in the oral care segments of removable oral appliances, dentures, removable orthodontics, retainers and protective mouth guards.

Group Pharmaceuticals Ltd shares the same values with bonyf in being at the forefront of oral care innovations, committed to bringing the best oral care science to India. With three facilities across India, manufacturing multiple dosage forms, the facility at Tarapur, near Mumbai, is specially designed and equipped to manufacture moisture sensitive tablets requiring strict humidity control. The facilities are cGMP, PIC/S and WHO compliant. The internal SOPs are designed to be above statutory requirements, enabling them to achieve several ISO certifications. A month ago, Group Pharmaceuticals succeeded in the certification as to produce Medical Devices Class a and b, successful testing completed for the first bonyf selected formulation, both cornerstones for a successful alliance between the two oral care manufacturing experts.

The bonyf and Group Pharmaceuticals Ltd alliance brings two R&D oral care-driven manufacturing experts together offering the global golden standard formula for denture cleansing and disinfecting tablets known as NitrAdine® denture tablets. This formula, highly appreciated by dental professionals across Europe and backed by numerous scientific publications, will soon be available to the Indian population under the same trusted European brand name NitrAdine®. The formula holds other successful product applications for which we joined forces are planned as to ensure capacity needs. The licensing agreement activates manufacturing and distribution in India, ensuring accessibility and scalability for a broad and emerging market. Additionally, bonyf is introducing another highly acclaimed producta denture fixative cream known for its superior quality, also to be produced in India under the same licensing model. Production of these innovative products is planned to begin in early 2025, marking a new era of accessible, high-quality dental care solutions for India.

The alliance enforces not only the global ambition of the bonyf group as leading experts in innovative denture wearer solutions but paves the global competitiveness of the bonyf NitrAdine® cleansing & disinfecting tablets.

For more information, visit bonyf.com or contact investor@bonyf.com.

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market

 

fncls.ssp?fn=download2_file&code_str=a59f6d7ce5d503e9e2aef147115b59d3

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

fncls.ssp?fn=download2_file&code_str=22ff99682d7ba91c4d38251de9e3e1da

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Doornzelestraat 114 D
9000 Gent
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2040479

 
End of Announcement - EQS News Service

2040479  28-Nov-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2040479&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - bonyf NV
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.